This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Break-Out Stocks: The Search for Survivors

Vertex Pharmaceutical

One final breakout idea that's also in the biotechnology sector is Vertex Pharmaceutical (VRTX). This company is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of diseases. Vertex engaged in phase-I clinical trials and/or nonclinical activities with respect to a range of additional drug candidates, including compounds intended for the treatment of hepatitis C virus infection, cystic fibrosis and influenza. This stock has been uptrending nicely so far this year with shares up over 28%.

A couple of reasons to like Vertex here is because the stock is displaying some relative strength with shares up most of the day in this weak tape, and also because of an upcoming catalyst that could propel shares higher. Vertex is slated to present at an upcoming Robert W. Baird Health Care Conference in New York that will take place on Sept. 7 and 8.

If you take a look at the chart for Vertex, you'll see that this stock has two major breakout signals that could be setting up to trigger in the coming days or weeks. The first is a move above a key descending trend line that started back in early August when the stock was at $53 a share. A move above that trend line would be a bullish development for shares of VRTX since it's marked a level where sellers have showed up recently.

The second breakout signal will trigger if VRTX trades above some near-term overhead resistance at $47.50 and then above its 50-day moving average of $47.92 a share. If the stock clears both of those levels, then it will have a pretty resistance free clear path back towards $53 a share.

One could simply be a buyer of this stock on any weakness as long as it holds above its near-term support zone at around $44.50 to $43.30 a share. I would get out of this trade if the stock falls below those levels on strong volume. If you want to buy strength, then buy VRTX once it clears its 50-day moving average of $47.92 on big volume. Look for volume that's tracking close to or well above its three-month average volume of 2.17 million shares. I would stop out of that trade if the stock then moves back below that key descending trend line. I would add to any long position in VRTX if it clears $53 with volume.

This stock has a decent short interest since 4.1% of the tradable float is sold short by the bears. Those short-sellers have also been increasing their bets from the last reporting period by around 11.8%, or by about 898,000 shares. If this stock breaks out soon, then the bears could cover quickly sparking a big short-covering rally.

To see more breakout candidates like Universal Display (PANL), Regeneron Pharmaceuticals (REGN) and O-Reilly Automotive (ORLY), check out the Breakout Stocks of the Week portfolio on Stockpickr.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

-- Written by Roberto Pedone in Winderemere, Fla.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to Beconequity.com and maintains the website Maddmoney.net, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.

6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs